Results 171 to 180 of about 13,497 (214)

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Peptides, 2020
Accumulating evidence suggests that glucose-dependent insulinotropic polypeptide (GIP) in addition to its involvement in type 2 diabetic pathophysiology may be involved in the development of obesity and the pathogenesis of cardiovascular disease. In this review, we outline recent preclinical and clinical cardiovascular-related discoveries about GIP ...
Sebastian M Heimburger, Natasha C Bergmann, Robert Augustin   +2 more
exaly   +4 more sources

Evolutionary expression of glucose-dependent-insulinotropic polypeptide (GIP)

Regulatory Peptides, 2011
Glucose-dependent insulinotropic polypeptide (GIP) is a mammalian incretin hormone released into the circulation following nutrient ingestion. We examined the functional evolution of GIP and its relationship with insulin to delineate their respective roles in promoting nutrient efficiency.
Lisa I Jepeal, John R Finnerty, M Michael Wolfe   +2 more
exaly   +3 more sources

Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

Best Practice & Research Clinical Endocrinology & Metabolism, 2004
The 42 amino acid polypeptide glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide (GIP) is released from intestinal K-cells in response to nutrient ingestion. Based on animal studies, the peptide was initially assumed to act as an endogenous inhibitor of gastric acid secretion.
Juris J. Meier, Michael A. Nauck
openaire   +1 more source

Glucose-dependent insulinotropic polypeptide – beyond the enteroinsular axis?

Current Opinion in Endocrinology and Diabetes, 2006
Purpose of review: Glucose-dependent insulinotropic polypeptide (GIP) plays an important role in the enteroinsular axis, stimulating insulin secretion. In addition, it has extrapancreatic actions, which may have pathophysiological relevance. This review highlights recent findings with regard to GIP's actions both within the enteroinsular axis and ...
Robertson, MD, Johnston, KL, Morgan, LM
openaire   +3 more sources

Glucose-dependent insulinotropic polypeptide and its role in obesity

Current Opinion in Endocrinology, Diabetes & Obesity, 2007
As we strive to improve our understanding of the factors that contribute to the pathogenesis of obesity, it is certainly logical to speculate that a nutrition-dependent component emanating from the gastrointestinal tract, which has the capacity to regulate insulin expression, could represent an etiologic factor in this serious health issue.
Diane H, Song, M Michael, Wolfe
openaire   +2 more sources

Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders

Expert Opinion on Therapeutic Targets, 2018
Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) exert pleiotropic effects on endocrine pancreas and nervous system. Expression of GIP and GIP receptor (GIPR) in neurons, their roles in neurogenesis, synaptic plasticity, neurotransmission, and neuromodulation uniquely position GIPR for ...
Mahip K Verma, Kumar V S Nemmani
exaly   +3 more sources

Safety of native glucose-dependent insulinotropic polypeptide in humans

Peptides
In this systematic review, we assessed the safety and possible safety events of native glucose-dependent insulinotropic polypeptide (GIP)(1-42) in human studies with administration of synthetic human GIP. We searched the PubMed database for all trials investigating synthetic human GIP(1-42) administration. A total of 67 studies were included.
Helsted, Mads M., Schaltz, Nina L., Gasbjerg, Lærke S., Christensen, Mikkel B., Vilsbøll, Tina, Knop, Filip K.   +5 more
openaire   +3 more sources

Central Regulation of Glucose-Dependent Insulinotropic Polypeptide Secretion

2010
Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are potent stimulators of glucose-dependent insulin secretion, a phenomenon known as incretin effect. After food ingestion, the circulating levels of GIP and GLP-1 rise more quickly than could be explained by the arrival of unabsorbed nutrients that have a direct ...
Maria P, Yavropoulou, John G, Yovos
openaire   +2 more sources

Structure-Activity Relationships of Glucose-Dependent Insulinotropic Polypeptide (GIP)

Biological Chemistry, 2003
Six GIP(1-NH2) analogs were synthesized with modifications (de-protonation, N-methylation, reversed chirality, and substitution) at positions 1, 3, and 4 of the N-terminus, and additionally, a cyclized GIP derivative was synthesized. The relationship between altered structure to biological activity was assessed by measuring receptor binding affinity ...
Simon A, Hinke, Rick, Gelling, Susanne, Manhart, Francis, Lynn, Raymond A, Pederson, Kerstin, Kühn-Wache, Fred, Rosche, Hans-Ulrich, Demuth, David, Coy, Christopher H S, McIntosh   +9 more
openaire   +2 more sources

The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide

Diabetes, Obesity and Metabolism, 2023
Abstract Tirzepatide is a unimolecular co‐agonist of the glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors recently approved for the treatment of type 2 diabetes by the US Food and Drug Administration and the European Medicine Agency.
Lærke S. Gasbjerg, Mette M. Rosenkilde, Juris J. Meier, Jens J. Holst, Filip K. Knop   +4 more
openaire   +3 more sources